CDT
CDT Equity Inc.
$2.86
-1.38%
2026-08-21
About CDT Equity Inc.
CDT Equity Inc., a data-driven biopharmaceutical company, focuses on identifying, enhancing, and monetising therapeutic assets. The company's pipeline includes AZD1656, a glucokinase activator that is in Phase II trials for the treatment of autoimmune disorders, including uveitis, Hashimoto's thyroiditis, preterm labor, and renal transplant; AZD5658, which is in Phase I clinical trial for the treatment of Type 2 Diabetes Mellitus; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. It also provides treatments for inflammatory disorders, oncology, dermatology, rare diseases and animal health. The company was formerly known as Conduit Pharmaceuticals Inc. and changed its name to CDT Equity Inc. in August 2025. The company was founded in 2019 and is based in Naples, Florida.
Key Fundamentals
EPS (TTM)
$-81.60
ROE
-71.0%
Profit Margin
0.0%
Debt/Equity
0.81
Price/Book
0.20
Beta
1.49
Market Cap
$2.3M
Avg Volume (10D)
81K
Recent Breakout Signals
No recent breakout signals detected for CDT.
Recent Price Range (60 Days)
60D High
$28.90
60D Low
$2.53
Avg Volume
752K
Latest Close
$2.86
Get breakout alerts for CDT
Sign up for Breakout Scanner to receive daily notifications when CDT triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial.
CDT Equity Inc. (CDT) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors CDT daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. CDT operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.